Peanut Allergy Therapeutics| A Pipeline Analysis Report 2018| Technavio
LONDON--(BUSINESS WIRE)--Jul 6, 2018--Technavio has announced their latest pipeline analysis report on the . This report provides detailed insights into the clinical trials landscape of the gene therapy for peanut allergy therapeutics including molecules at pre-clinical and discovery stage.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180706005409/en/
Technavio has published a new report on the drug development pipeline for peanut allergy therapeutics, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report by presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
Peanut allergy therapeutics: Market overview
Peanut allergy is a type of food allergy, which is common in children as well as adults. It occurs when the immune system of the body depicts an abnormal response for one or more than one peanut proteins.
According to a senior analyst at Technavio for research on infectious and rare diseases, “Furthermore, peanut allergy is a leading cause of anaphylaxis and can also lead to death.”
Peanut allergy therapeutics: Segmentation analysis
This market research report segments the peanut allergy therapeutics market based on therapies employed that includes monotherapy and unknown, RoA (oral, sublingual, intravenous, intradermal, intradermal+intramuscular, transdermal, subcutaneous, and unknown), therapeutic modalities (vaccine, monoclonal antibody, biological, recombinant fusion protein, gene, peptide, small molecule, and unknown), targets for drugs under development (immune system, IgE, IL-2, IL-33, T-cell, TLR4, and unknown), MoA (immunomodulator, IgE inhibitor, T-cell modulator, TLR4 agonist, immunosuppressant, IL-2 stimulant, IL-33 inhibitor, and unknown), drugs under development (discovery, pre-clinical, phase I, phase I/II, phase II, and phase III), and recruitment status (recruiting, active not recruiting, completed, unknown and NA). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development LandscapeDrugs under development Indications coverage
Drug Development StrategiesTherapies employed RoA Therapeutic modality Geographical coverage
Recruitment StrategiesRecruitment status Gender Age Recruitment volume
Key CompaniesType of players Company overview
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180706005409/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL RETAIL FOOD/BEVERAGE RESEARCH SCIENCE GENERAL HEALTH
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 07/06/2018 03:22 PM/DISC: 07/06/2018 03:21 PM